Is Nvidia Still the Best AI Stock to Buy in 2026, or Is This Challenger?

The article favors Nvidia as the better AI-stock buy for most investors, citing triple-digit revenue and profit growth in its latest quarter and company guidance for 70% revenue growth in the next fiscal year; the stock trades at 24x forward earnings estimates. Cerebras says its Wafer-Scale Engine delivers inference answers up to 15 times faster than GPU solutions, while its cloud and other services revenue rose 281% to $126 million in the latest quarter. Cerebras shares are down 58% from their $350 first-day opening price and below the $185 IPO price; the article presents it as an opportunity for aggressive investors, while emphasizing its greater risk relative to Nvidia.

Analysis

The key distinction is workload economics, not peak speed. Cerebras could win latency-sensitive inference jobs where customers value response time enough to tolerate a specialized system; that does not establish a broad substitute for NVIDIA’s training, software, and networking stack. Its reported services growth is a demand signal, but not yet proof of durable, high-quality economics: verify recurring customer usage, customer concentration, gross margins, utilization, and the cost and lead time of deploying wafer-scale systems.

Second-order risk: AWS access can expand Cerebras distribution, while also placing it inside a buyer that develops competing in-house accelerators. Cloud-provider procurement could therefore validate the technology but constrain pricing and bargaining power. For NVIDIA, credible inference alternatives matter most if they lower customers’ total cost per token and reduce accelerator utilization or pricing—not merely if a benchmark shows faster answers.

Near term, CBRS’s post-IPO volatility makes headline-driven entry risky; the next 1–3 months hinge on customer and deployment evidence, not speed claims. Over 6–18 months, the structural test is whether Cerebras can scale supply and repeat deployments while NVIDIA sustains platform attach and guidance. Contrarian view: the challenger’s drawdown may tempt investors to equate a cheaper entry with a margin of safety, despite limited evidence in the article on profitability or unit economics. No clean outright short of NVIDIA follows from this evidence.

Key Decisions for Investors

• Keep NVDA as the higher-conviction core AI exposure; do not reduce it solely on Cerebras’s company-reported speed claims. Reassess if NVIDIA’s guidance or accelerator demand weakens, or if customers show sustained migration of material workloads.
• Treat CBRS as a watchlist/speculative position rather than a benchmark-led buy. Before adding, seek evidence of repeat deployments, customer concentration, gross margin, utilization, and capital requirements; use staged entry given IPO volatility.
• Monitor AWS’s role as both distribution channel and potential competing accelerator supplier. Evidence of material, recurring Cerebras workloads through AWS would strengthen the adoption case; evidence of limited access or displacement by in-house chips would weaken it.
• For the next 1–3 months, favor event-driven diligence over a forced NVDA/CBRS pair trade. A relative short in CBRS is not justified without valuation, lockup, liquidity, and customer-economics data.